The National Institutes of Health (NIH) defines a Clinical Trial as a research study in which one or more human subjects are prospectively assigned to one or more interventions. Clinical trials help develop novel drugs (Investigational Products) by providing early access to patients who volunteer to participate in the research study.
Carolina BioOncology Institute and our expert Providers participate in the national clinical trials listed below. The eligibility criteria enables patients with advanced solid tumors to access these Investigational Products. Over the past 15 years, our Clinic has opened over 100 Oncology clinical trials and our experienced staff are happy to discuss options for determining trial eligibility Please view the list of trials below that are currently enrolling patients:
Abbvie M16-573
A Phase 1 First-in-Human Study with ABBV-155 Alone and in Combination with Taxane Therapy in Adults with Relapsed and/or Refractory Solid Tumors
Abbvie M19-037
A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 and ABBV-368 with and without ABBV-181 in Subjects with Locally Advanced or Metastatic Solid Tumors.
Abbvie M19-345
A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination with ABBV-181 in Subjects with Locally Advanced or Metastatic Solid Tumors
AbbVie M20-111
A Phase 1 first-in-human study evaluating safety and efficacy of ABBV-637 as either monotherapy or in combination in adult subjects with relapsed and refractory solid tumors
Abbvie M20-124
A Phase 1, Multi-center, Open Label First-in-Human Study with ABBV-CLS-579 Alone and in Combination with aPD-1 in Subjects with Locally Advanced or Metastatic Tumors
AbbVie M20-431
A Phase 1 Study with ABBV-CLS-484 Alone and in Combination in Subjects with Locally Advanced or Metastatic Tumors
Alkermes ALKS 4230-001
A Phase 1 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Apros APR003-001
A Phase 1 dose escalation study to evaluate safety, tolerability, and pharmacokinetics/pharmacodynamics of APR003 in patients with advanced colorectal cancer (CRC) with malignant liver lesions
Arcus AB154CSP0001
A Phase I Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants with Advanced Malignancies
Astra Zeneca D9950C00001
A Phase 1 First-in-human Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD8701 Administered Intravenously as Monotherapy and in Combination with Durvalumab (MEDI4736) in Participants with Advanced Solid Tumors
Atreca ATRC-101-A01
A First-in-Human Phase 1b Dose Escalation Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATRC-101 in Adults with Advanced Solid Malignancies
Conjupro CPO-100-US-101
A Phase 1, Multi-Center, Single Agent Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of CPO-100 in Adult Patients with Advanced Solid Tumors
FLX Bio FLX475-02
Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination with Pembrolizumab in Advanced Cancer.
Repertoire TT – 101
A Phase 1/2 Study of Deep IL-15 Loaded T-Cells Alone and in Combination with Pembrolizumab in Patients with Select Solid Tumors and Lymphomas
Top Alliance Tab001-01
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB001 in Subjects with Advanced Malignancies
InCyte INCAGN 2385-201
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti–PD-1), INCAGN02385 (Anti–LAG-3), and INCAGN02390 (Anti–TIM-3) in participants with Select Advanced Malignancies
I-Mab TJ033721STM101
Phase 1 study of TJ033721 in subjects with advanced or metastatic solid tumors.
Jounce JTX 8064-101
Phase 1 First-in-Human Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX 8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumor Malignancies
Macrogenics MCG018
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti–B7-H3 Antibody Drug Conjugate) Alone and in Combination with MGA012 (Anti–PD-1 Antibody) in Patients with Advanced Solid Tumors.
MedImmune D6770C00001
A Phase 1, First-in-Human, Multicenter, Open-label, Dose-escalation Study of IPH5201 as Monotherapy or in Combination with Durvalumab ± Oleclumab in Advanced Solid Tumors
Molecular Templates MT-6402-001
A Phase 1 Open-label, Multicenter, Dose-ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MT-6402 in Subjects with Advanced Solid Cancer That Expresses PD-L1.
Next Cure NC762-01
A Phase 1/Phase 2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC762 in Subjects with Advanced or Metastatic Solid Tumors
Nuvation NUV-422-02
Phase 1/2 Dose Escalation, Safety, Pharmacokinetics, and Efficacy Study of NUV-422 in Adults with Recurrent or Refractory High-grade Gliomas and Solid Tumors
Repertoire PRIME- 102
A Phase 1/2 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of RPTR-168 in Patients with Relapsed/Refractory HPV-16 E6/E7 Positive Tumors and Melanoma
TAB004-01
TAB004-01 – A First-in-Human, Multicenter, Open-Label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 in Subjects with Advanced Solid Malignancies including Lymphoma
Tempest TPST 1120
A Phase 1/1b Open-label, Dose-escalation and Dose-expansion Study of TPST-1120 as a Single Agent or in Combination with Systemic Anti-Cancer Therapies in Subjects with Advanced Solid Tumors
Tempest TPST 1495-001
A Phase 1a/1b Open-label, Dose-Escalation and Expansion Study of TPST-1495 as a Single Agent and in Combination with Pembrolizumab in Subjects with Solid Tumors